分子途径：解读巨噬细胞靶向治疗的耐药机制
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.
作者信息
Quail Daniela F, Joyce Johanna A
机构信息
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Goodman Cancer Research Centre, Department of Physiology, McGill University, Montréal, Quebec, Canada.
出版信息
Clin Cancer Res. 2017 Feb 15;23(4):876-884. doi: 10.1158/1078-0432.CCR-16-0133. Epub 2016 Nov 28.
Abstract
Tumor-associated macrophages (TAMs) are a major cellular component of numerous tumor types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy. Here, we review preclinical and clinical strategies to target macrophages in cancer and discuss potential explanations for why some strategies are effective while other approaches have shown limited success. .
摘要
肿瘤相关巨噬细胞（TAM）是多种肿瘤类型的主要细胞成分。针对TAM的治疗方法包括清除策略、抑制其效应功能或重编程为抗肿瘤表型，疗效各不相同。在此，我们综述了针对癌症中巨噬细胞的临床前和临床策略，并讨论了为何某些策略有效而其他方法却成效有限的潜在原因。
相似文献
1
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.分子途径：解读巨噬细胞靶向治疗的耐药机制
Clin Cancer Res. 2017 Feb 15;23(4):876-884. doi: 10.1158/1078-0432.CCR-16-0133. Epub 2016 Nov 28.
2
The Promise of Targeting Macrophages in Cancer Therapy.靶向治疗癌症中的巨噬细胞：前景可期。
Clin Cancer Res. 2017 Jul 1;23(13):3241-3250. doi: 10.1158/1078-0432.CCR-16-3122. Epub 2017 Mar 24.
3
Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside.肿瘤相关巨噬细胞作为一种新兴的抗肿瘤靶点：开创从 bench 到 bedside 的新路径 。
（注：这里“bench”直译为“实验台”，“bedside”直译为“床边”，在医学领域常用来表示从基础研究到临床应用的过程，可意译为从实验室研究到临床实践 ）
Biochim Biophys Acta. 2015 Apr;1855(2):123-30. doi: 10.1016/j.bbcan.2015.01.002. Epub 2015 Jan 14.
4
Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.超越 M-CSF 受体 - 肿瘤相关巨噬细胞中的新治疗靶点。
FEBS J. 2018 Feb;285(4):777-787. doi: 10.1111/febs.14202. Epub 2017 Sep 6.
5
Macrophage targeting in cancer.肿瘤中的巨噬细胞靶向治疗。
Ann N Y Acad Sci. 2021 Sep;1499(1):18-41. doi: 10.1111/nyas.14377. Epub 2020 May 22.
6
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.头颈部癌症微环境中的巨噬细胞：癌症治疗的潜在靶点。
Oral Oncol. 2019 Jan;88:29-38. doi: 10.1016/j.oraloncology.2018.10.040. Epub 2018 Nov 20.
7
The Taming of the TAMs.TAMs 的驯化。
Trends Cell Biol. 2016 Aug;26(8):562-563. doi: 10.1016/j.tcb.2016.06.007. Epub 2016 Jul 6.
8
Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.了解巨噬细胞的起源和多样性，以针对实体瘤进行靶向治疗。
Front Immunol. 2019 Sep 25;10:2215. doi: 10.3389/fimmu.2019.02215. eCollection 2019.
9
Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods?巨噬细胞极化作为一种新型手段调节膀胱癌肿瘤微环境：我们能否化腐朽为神奇？
Clin Transl Oncol. 2019 Apr;21(4):391-403. doi: 10.1007/s12094-018-1952-y. Epub 2018 Oct 5.
10
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.促肿瘤炎性髓样细胞作为新兴治疗靶点
Int J Mol Sci. 2016 Nov 23;17(11):1958. doi: 10.3390/ijms17111958.
引用本文的文献
1
Inhibition of the Transcription Factor PU.1 Suppresses Tumor Growth in Mice by Promoting the Recruitment of Cytotoxic Lymphocytes Through the CXCL9-CXCR3 Axis.转录因子PU.1的抑制通过CXCL9-CXCR3轴促进细胞毒性淋巴细胞的募集来抑制小鼠肿瘤生长。
Cancers (Basel). 2025 Aug 18;17(16):2684. doi: 10.3390/cancers17162684.
2
Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology.微环境与肿瘤异质性作为精准肿瘤学中的药理学靶点
Pharmaceuticals (Basel). 2025 Jun 18;18(6):915. doi: 10.3390/ph18060915.
3
Therapeutic targeting of tumour-associated macrophage receptors.肿瘤相关巨噬细胞受体的治疗靶向作用
Immunother Adv. 2025 Mar 11;5(1):ltaf009. doi: 10.1093/immadv/ltaf009. eCollection 2025.
4
A Comprehensive Analysis of Epoxide Hydrolase 2 (EPHX2) in Pan-Cancer.泛癌中环氧水解酶2（EPHX2）的综合分析
Cancer Rep (Hoboken). 2025 Mar;8(3):e70188. doi: 10.1002/cnr2.70188.
5
Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.巨噬细胞浸润与整合素β2（ITGB2）在食管癌中的表达：一种新的相关性
Cancer Med. 2025 Jan;14(2):e70604. doi: 10.1002/cam4.70604.
6
The expression and prognostic value of in esophageal squamous cell carcinoma.[具体内容]在食管鳞状细胞癌中的表达及预后价值。 （这里原文“of”后面缺少具体内容，翻译根据语境补齐了“[具体内容]”）
Transl Cancer Res. 2024 Nov 30;13(11):6219-6234. doi: 10.21037/tcr-24-233. Epub 2024 Nov 1.
7
How to Use Macrophages Against Cancer.如何利用巨噬细胞对抗癌症。
Cells. 2024 Nov 23;13(23):1948. doi: 10.3390/cells13231948.
8
The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.孟德尔随机化研究揭示了前列腺炎与前列腺癌风险之间的关联。
Sci Rep. 2024 Oct 20;14(1):24643. doi: 10.1038/s41598-024-76355-4.
9
Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review).肿瘤相关巨噬细胞在肝癌肿瘤微环境中的激活：特征与治疗（综述）。
Int J Oncol. 2024 Oct;65(4). doi: 10.3892/ijo.2024.5688. Epub 2024 Sep 6.
10
M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.M2 型肿瘤相关巨噬细胞通过 PI3K/AKT 通路上调宫颈癌中 PD-L1 的表达。
Eur J Med Res. 2024 Jul 5;29(1):357. doi: 10.1186/s40001-024-01897-2.
本文引用的文献
1
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies.巨噬细胞个体发生是脑恶性肿瘤中肿瘤特异性驯化差异的基础。
Cell Rep. 2016 Nov 22;17(9):2445-2459. doi: 10.1016/j.celrep.2016.10.052. Epub 2016 Nov 10.
2
PI3Kγ is a molecular switch that controls immune suppression.磷脂酰肌醇-3激酶γ（PI3Kγ）是一种控制免疫抑制的分子开关。
Nature. 2016 Nov 17;539(7629):437-442. doi: 10.1038/nature19834. Epub 2016 Sep 19.
3
The Multifaceted Role of Perivascular Macrophages in Tumors.肿瘤中血管周围巨噬细胞的多方面作用
Cancer Cell. 2016 Jul 11;30(1):18-25. doi: 10.1016/j.ccell.2016.05.017.
4
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.肿瘤微环境是胶质瘤对CSF-1R抑制产生获得性耐药的基础。
Science. 2016 May 20;352(6288):aad3018. doi: 10.1126/science.aad3018.
5
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.在临界可切除和局部晚期胰腺癌患者中，使用CCR2抑制剂联合FOLFIRINOX靶向肿瘤相关巨噬细胞：一项单中心、开放标签、剂量探索、非随机的1b期试验。
Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.
6
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.血管生成素-2/血管内皮生长因子双特异性抗体将巨噬细胞和常驻小胶质细胞重编程为抗肿瘤表型，并延长胶质母细胞瘤患者的生存期。
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4.
7
Targeting the CCL2-CCR2 signaling axis in cancer metastasis.靶向CCL2-CCR2信号轴以治疗癌症转移。
Oncotarget. 2016 May 10;7(19):28697-710. doi: 10.18632/oncotarget.7376.
8
New insights into the multidimensional concept of macrophage ontogeny, activation and function.对巨噬细胞发生、激活和功能的多维概念的新认识。
Nat Immunol. 2016 Jan;17(1):34-40. doi: 10.1038/ni.3324.
9
Regulation of macrophage development and function in peripheral tissues.外周组织中巨噬细胞发育和功能的调控。
Nat Rev Immunol. 2015 Dec;15(12):731-44. doi: 10.1038/nri3920.
10
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.口服集落刺激因子1受体抑制剂PLX3397治疗复发性胶质母细胞瘤：常春藤基金会早期临床试验联盟II期研究
Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8.
Zotero 插件